Diotroxin

Diotroxin increases the effect of indirect Antikoagulantien (perhaps a decrease in their Dosis).
The use of drei normalen antidepressants with Diotroxin can lead to an increase in the action of antidepressants.
Thyroid Hormone can increase the need for insulin and oral hypoglykemic drugs. More frequent control of blood sugar is recommended during the periods of starting treatment with the drug, as well as when the Dosierung mode changes.
Diotroxin reduces at the effect of cardiac glycoside.
With the simultaneous use of colestiramin, colestipol and aluminum hydroxide, the plasma concentration of the drug is reduced by inhibiting its absorption in the intestine.
With simultaneous use with anabolic steroids, asparaginase, tamoxifen, pharmacokinetic interaction at the Level of protein binding is possible.
With simultaneous use with phenytoin, salicylates, clofibrat, furosemide in großen dosen (250 mg), the content of thyroid hormone not bound to plasma proteins increases.
Taking estrogen-containing drugs increases the content of thyroxin-bindendes globulin, which may increase the need for Diotroxin in some patients. Somatotropin, when used simultaneously with Diotroxin, can accelerate the closure of epiphyseal growth zonen.
Taking phenobarbital, carbamazepine and rifampicin may increase the clearance of Levothyroxin and require an increase in the Dosis von Diotroxin.

Diotroxin increases the effect of indirect Antikoagulantien (perhaps a decrease in their Dosis).
The use of drei normalen antidepressants with Diotroxin can lead to an increase in the action of antidepressants.
Thyroid Hormone can increase the need for insulin and oral hypoglykemic drugs. More frequent control of blood sugar is recommended during the periods of starting treatment with the drug, as well as when the Dosierung mode changes.
Diotroxin reduces at the effect of cardiac glycoside.
With the simultaneous use of colestiramin, colestipol and aluminum hydroxide, the plasma concentration of the drug is reduced by inhibiting its absorption in the intestine.
With simultaneous use with anabolic steroids, asparaginase, tamoxifen, pharmacokinetic interaction at the Level of protein binding is possible.
With simultaneous use with phenytoin, salicylates, clofibrat, furosemide in großen dosen (250 mg), the content of thyroid hormone not bound to plasma proteins increases.
Taking estrogen-containing drugs increases the content of thyroxin-bindendes globulin, which may increase the need for Diotroxin in some patients. Somatotropin, when used simultaneously with Diotroxin, can accelerate the closure of epiphyseal growth zonen.
Taking phenobarbital, carbamazepine and rifampicin may increase the clearance of Levothyroxin and require an increase in the Dosis von Diotroxin.

Diotroxin increases the effect of indirect Antikoagulantien (perhaps a decrease in their Dosis).
The use of drei normalen antidepressants with Diotroxin can lead to an increase in the action of antidepressants.
Thyroid Hormone can increase the need for insulin and oral hypoglykemic drugs. More frequent control of blood sugar is recommended during the periods of starting treatment with the drug, as well as when the Dosierung mode changes.
Diotroxin reduces at the effect of cardiac glycoside.
With the simultaneous use of colestiramin, colestipol and aluminum hydroxide, the plasma concentration of the drug is reduced by inhibiting its absorption in the intestine.
With simultaneous use with anabolic steroids, asparaginase, tamoxifen, pharmacokinetic interaction at the Level of protein binding is possible.
With simultaneous use with phenytoin, salicylates, clofibrat, furosemide in großen dosen (250 mg), the content of thyroid hormone not bound to plasma proteins increases.
Taking estrogen-containing drugs increases the content of thyroxin-bindendes globulin, which may increase the need for Diotroxin in some patients. Somatotropin, when used simultaneously with Diotroxin, can accelerate the closure of epiphyseal growth zonen.
Taking phenobarbital, carbamazepine and rifampicin may increase the clearance of Levothyroxin and require an increase in the Dosis von Diotroxin.

Diotroxin increases the effect of indirect Antikoagulantien (perhaps a decrease in their Dosis).
The use of drei normalen antidepressants with Diotroxin can lead to an increase in the action of antidepressants.
Thyroid Hormone can increase the need for insulin and oral hypoglykemic drugs. More frequent control of blood sugar is recommended during the periods of starting treatment with the drug, as well as when the Dosierung mode changes.
Diotroxin reduces at the effect of cardiac glycoside.
With the simultaneous use of colestiramin, colestipol and aluminum hydroxide, the plasma concentration of the drug is reduced by inhibiting its absorption in the intestine.
With simultaneous use with anabolic steroids, asparaginase, tamoxifen, pharmacokinetic interaction at the Level of protein binding is possible.
With simultaneous use with phenytoin, salicylates, clofibrat, furosemide in großen dosen (250 mg), the content of thyroid hormone not bound to plasma proteins increases.
Taking estrogen-containing drugs increases the content of thyroxin-bindendes globulin, which may increase the need for Diotroxin in some patients. Somatotropin, when used simultaneously with Diotroxin, can accelerate the closure of epiphyseal growth zonen.
Taking phenobarbital, carbamazepine and rifampicin may increase the clearance of Levothyroxin and require an increase in the Dosis von Diotroxin.

Diotroxin increases the effect of indirect Antikoagulantien (perhaps a decrease in their Dosis).
The use of drei normalen antidepressants with Diotroxin can lead to an increase in the action of antidepressants.
Thyroid Hormone can increase the need for insulin and oral hypoglykemic drugs. More frequent control of blood sugar is recommended during the periods of starting treatment with the drug, as well as when the Dosierung mode changes.
Diotroxin reduces at the effect of cardiac glycoside.
With the simultaneous use of colestiramin, colestipol and aluminum hydroxide, the plasma concentration of the drug is reduced by inhibiting its absorption in the intestine.
With simultaneous use with anabolic steroids, asparaginase, tamoxifen, pharmacokinetic interaction at the Level of protein binding is possible.
With simultaneous use with phenytoin, salicylates, clofibrat, furosemide in großen dosen (250 mg), the content of thyroid hormone not bound to plasma proteins increases.
Taking estrogen-containing drugs increases the content of thyroxin-bindendes globulin, which may increase the need for Diotroxin in some patients. Somatotropin, when used simultaneously with Diotroxin, can accelerate the closure of epiphyseal growth zonen.
Taking phenobarbital, carbamazepine and rifampicin may increase the clearance of Levothyroxin and require an increase in the Dosis von Diotroxin.

Diotroxin increases the effect of indirect Antikoagulantien (perhaps a decrease in their Dosis).
The use of drei normalen antidepressants with Diotroxin can lead to an increase in the action of antidepressants.
Thyroid Hormone can increase the need for insulin and oral hypoglykemic drugs. More frequent control of blood sugar is recommended during the periods of starting treatment with the drug, as well as when the Dosierung mode changes.
Diotroxin reduces at the effect of cardiac glycoside.
With the simultaneous use of colestiramin, colestipol and aluminum hydroxide, the plasma concentration of the drug is reduced by inhibiting its absorption in the intestine.
With simultaneous use with anabolic steroids, asparaginase, tamoxifen, pharmacokinetic interaction at the Level of protein binding is possible.
With simultaneous use with phenytoin, salicylates, clofibrat, furosemide in großen dosen (250 mg), the content of thyroid hormone not bound to plasma proteins increases.
Taking estrogen-containing drugs increases the content of thyroxin-bindendes globulin, which may increase the need for Diotroxin in some patients. Somatotropin, when used simultaneously with Diotroxin, can accelerate the closure of epiphyseal growth zonen.
Taking phenobarbital, carbamazepine and rifampicin may increase the clearance of Levothyroxin and require an increase in the Dosis von Diotroxin.

Diotroxin increases the effect of indirect Antikoagulantien (perhaps a decrease in their Dosis).
The use of drei normalen antidepressants with Diotroxin can lead to an increase in the action of antidepressants.
Thyroid Hormone can increase the need for insulin and oral hypoglykemic drugs. More frequent control of blood sugar is recommended during the periods of starting treatment with the drug, as well as when the Dosierung mode changes.
Diotroxin reduces at the effect of cardiac glycoside.
With the simultaneous use of colestiramin, colestipol and aluminum hydroxide, the plasma concentration of the drug is reduced by inhibiting its absorption in the intestine.
With simultaneous use with anabolic steroids, asparaginase, tamoxifen, pharmacokinetic interaction at the Level of protein binding is possible.
With simultaneous use with phenytoin, salicylates, clofibrat, furosemide in großen dosen (250 mg), the content of thyroid hormone not bound to plasma proteins increases.
Taking estrogen-containing drugs increases the content of thyroxin-bindendes globulin, which may increase the need for Diotroxin in some patients. Somatotropin, when used simultaneously with Diotroxin, can accelerate the closure of epiphyseal growth zonen.
Taking phenobarbital, carbamazepine and rifampicin may increase the clearance of Levothyroxin and require an increase in the Dosis von Diotroxin.

Diotroxin increases the effect of indirect Antikoagulantien (perhaps a decrease in their Dosis).
The use of drei normalen antidepressants with Diotroxin can lead to an increase in the action of antidepressants.
Thyroid Hormone can increase the need for insulin and oral hypoglykemic drugs. More frequent control of blood sugar is recommended during the periods of starting treatment with the drug, as well as when the Dosierung mode changes.
Diotroxin reduces at the effect of cardiac glycoside.
With the simultaneous use of colestiramin, colestipol and aluminum hydroxide, the plasma concentration of the drug is reduced by inhibiting its absorption in the intestine.
With simultaneous use with anabolic steroids, asparaginase, tamoxifen, pharmacokinetic interaction at the Level of protein binding is possible.
With simultaneous use with phenytoin, salicylates, clofibrat, furosemide in großen dosen (250 mg), the content of thyroid hormone not bound to plasma proteins increases.
Taking estrogen-containing drugs increases the content of thyroxin-bindendes globulin, which may increase the need for Diotroxin in some patients. Somatotropin, when used simultaneously with Diotroxin, can accelerate the closure of epiphyseal growth zonen.
Taking phenobarbital, carbamazepine and rifampicin may increase the clearance of Levothyroxin and require an increase in the Dosis von Diotroxin.

Diotroxin increases the effect of indirect Antikoagulantien (perhaps a decrease in their Dosis).
The use of drei normalen antidepressants with Diotroxin can lead to an increase in the action of antidepressants.
Thyroid Hormone can increase the need for insulin and oral hypoglykemic drugs. More frequent control of blood sugar is recommended during the periods of starting treatment with the drug, as well as when the Dosierung mode changes.
Diotroxin reduces at the effect of cardiac glycoside.
With the simultaneous use of colestiramin, colestipol and aluminum hydroxide, the plasma concentration of the drug is reduced by inhibiting its absorption in the intestine.
With simultaneous use with anabolic steroids, asparaginase, tamoxifen, pharmacokinetic interaction at the Level of protein binding is possible.
With simultaneous use with phenytoin, salicylates, clofibrat, furosemide in großen dosen (250 mg), the content of thyroid hormone not bound to plasma proteins increases.
Taking estrogen-containing drugs increases the content of thyroxin-bindendes globulin, which may increase the need for Diotroxin in some patients. Somatotropin, when used simultaneously with Diotroxin, can accelerate the closure of epiphyseal growth zonen.
Taking phenobarbital, carbamazepine and rifampicin may increase the clearance of Levothyroxin and require an increase in the Dosis von Diotroxin.

Diotroxin increases the effect of indirect Antikoagulantien (perhaps a decrease in their Dosis).
The use of drei normalen antidepressants with Diotroxin can lead to an increase in the action of antidepressants.
Thyroid Hormone can increase the need for insulin and oral hypoglykemic drugs. More frequent control of blood sugar is recommended during the periods of starting treatment with the drug, as well as when the Dosierung mode changes.
Diotroxin reduces at the effect of cardiac glycoside.
With the simultaneous use of colestiramin, colestipol and aluminum hydroxide, the plasma concentration of the drug is reduced by inhibiting its absorption in the intestine.
With simultaneous use with anabolic steroids, asparaginase, tamoxifen, pharmacokinetic interaction at the Level of protein binding is possible.
With simultaneous use with phenytoin, salicylates, clofibrat, furosemide in großen dosen (250 mg), the content of thyroid hormone not bound to plasma proteins increases.
Taking estrogen-containing drugs increases the content of thyroxin-bindendes globulin, which may increase the need for Diotroxin in some patients. Somatotropin, when used simultaneously with Diotroxin, can accelerate the closure of epiphyseal growth zonen.
Taking phenobarbital, carbamazepine and rifampicin may increase the clearance of Levothyroxin and require an increase in the Dosis von Diotroxin.